Picture of Divi's Laboratories logo

DIVISLAB — Divi's Laboratories News Story

0.000.00%
in flag iconLast trade - 00:00
HealthcareConservativeLarge CapHigh Flyer

India's Divi's Labs gains on BofA's double upgrade to "buy"

** Divi's Laboratories  DIVI.NS  up 1.6% at ~3,680 rupees,
among top Nifty 50  .NSEI  gainers
    ** BofA Securities double upgrades the drug ingredients
maker's stock to "buy" from "underperform" on improving earnings
outlook and attractive valuation; raises PT to 4,025 rupees
    ** Brokerage says Divi's is more compelling due to lower
risk to earnings growth than at US-focused generic drug makers,
who are susceptible to pricing uncertainties
    ** Expects Divi's EBITDA margins to rise to 33% by FY26 (vs
35% pre-COVID), after likely bottoming out at 27% in FY24
    ** Despite the upgrade, analysts' avg rating on Divi's
remains "sell", per LSEG data
    ** Wipro  WIPR.NS  is the only other Nifty 50 stock with an
avg "sell" rating
    ** DIVI trims YTD losses to ~6%; is among three stocks on
20-member Nifty pharma  .NIPHARM  in the red this year

 (Reporting by Nandan Mandayam in Bengaluru)
 ((Nandan.Mandayam@thomsonreuters.com; Mobile: +91 9591011727;))

Recent news on Divi's Laboratories

See all news